Therapeutic Potential of Omega-3 Fatty Acids Supplementation in Dry Macular Degeneration and Stargardt Disease

Inclusion Criteria: * Men and women ages from 18 to 85 years old. * Group 1: For moderate dry macular degeneration the BCVA must be between 50 and 70 (ETDRS) at Screening Visit V1. There must be a large drusen \>125 µm within 1mm from the centre of the fovea. Geographic atrophy can be present but must be \>300 µm away from centre of fovea; * Group 2: For severe dry macular degeneration the BCVA must be between 41 and 49 (ETDRS) at Screening Visit V1. Geographic atrophy can involve the fovea but must be \<2500 µm in diameter or any size GA but \>200 µm from centre of fovea anywhere; * Group 3: For moderate Stargardt disease the BCVA must be between 50 and 70 (ETDRS) at Screening Visit V1. The geographic area must be \<2.0 mm in diameter anywhere; * Group 4: For severe Stargardt disease the BCVA must be between 41 and 49 (ETDRS) at Screening Visit V1. The geographic area must be \<2.5 mm in diameter anywhere; * Willingness to take the randomised trial investigational product for 6 months; * Willingness to consent and undergo the examinations/blood testing at the visits; * Be able to swallow large soft gel capsules; * Take other supplements as usual; The EPA and DHA intake must be less than 1200 mg/day. Exclusion Criteria: * Any ocular disease in either eye including: Diabetic retinopathy, Central serous retinopathy, Epiretinal membrane, Optic atrophy, Macular hole or pseudohole, Retinal vein occlusion, Amblyopia; * Previous wet AMD in the study eye; * Any previous ocular surgery, which may influence progression of dry macular degeneration e.g. trabeculectomy, previous refractive surgery, pterygium surgery. Cataract surgery more than 6 months is not an exclusion criterion unless a complication has occurred during surgery; * Any topical medication administered for other diseases such as glaucoma. Artificial tears up to 3/day will be allowed; * Any ocular condition such as allergic conjunctivitis, moderate to severe dry eyes, scleritis, uveitis, keratitis, ocular Herpes Simplex keratitis, ectropion, entropion, ocular surface scaring; * Any systemic conditions such as gastrointestinal disease e.g. irritable bowel syndrome, Crohn's disease, cancer, etc; * Any drugs which could affect the eye administered up to 6 months before screening e.g.: Steroids, Ethambutol, Tamoxifen, Chloroquine, Hydroxychloroquine; * Any condition that would not allow follow up e.g. alcoholism or drug abuse; * Allergy to any ingredients of the active or placebo pills. * Pregnant or lactating; * Current use of EPA/DHA supplements in excess of 1200 mg/day; * History of liver disease; * Anti-coagulation therapy such as warfarin/heparin/aspirin/dabigatran/ clopidogrel etc; * Bleeding tendencies e.g. coagulopathies; * History of atrial fibrillation; * Inability to give informed consent (impaired mental capacity e.g. psychiatric deficit); * Smokers or patients who have not been completely smoke free over the past 5 years.